FAPI PET-CT vs FDG PET-CT in Ovarian Cancer
FAPI PET-CT is not currently included in standard clinical guidelines for ovarian cancer imaging, and FDG PET-CT remains the guideline-recommended nuclear medicine modality for recurrence detection and treatment response assessment. 1
Current Guideline Recommendations
The 2025 ACR Appropriateness Criteria and 2023 ESMO guidelines establish the standard imaging approach for ovarian cancer:
For Suspected or Known Recurrence
- CT abdomen/pelvis with IV contrast is the primary imaging modality (sensitivity 58-84%, specificity 59-100%) 1
- FDG PET-CT is recommended as a complementary study with sensitivity of 88% and specificity of 89% for detecting recurrent epithelial ovarian cancer 1
- FDG PET-CT should be used as an adjunct when CT is indeterminate or when there is high clinical suspicion (rising CA-125, worsening symptoms) but negative CT findings 1
For Treatment Response Assessment
- CT with contrast and FDG PET-CT are recommended complementary studies to evaluate posttreatment response 1
- Resolution or regression of metabolic activity on FDG PET-CT indicates favorable treatment response 1
Emerging Research on FAPI PET-CT
While not yet guideline-endorsed, recent research demonstrates FAPI PET-CT's superior performance in specific scenarios:
Superior Detection of Peritoneal Metastases
FAPI PET-CT significantly outperforms FDG PET-CT for peritoneal carcinomatosis detection:
- Sensitivity: 95-98% vs. 60-76% for FDG PET-CT 2, 3, 4
- Higher SUVmax values for peritoneal lesions (17.31 vs. 13.68, p=0.026) 2
- Higher peritoneal cancer index (PCI) scores correlating with surgical findings 2, 5
Lymph Node Metastases
- Detection rate: 96.8-99.5% vs. 80.4-91.4% for FDG PET-CT 2
- Sensitivity: 80.6-94.4% vs. 61.1-61.3% for FDG PET-CT 2, 5
Clinical Impact in Research Settings
- Led to upstaging in 14.3-33.3% of patients 2
- Changed management in 10.7-22.2% of cases 2, 5
- Identified additional lesions not seen on FDG PET-CT in 33.3% of patients 6
Specific Scenario Where FAPI Shows Promise
The most compelling research evidence supports FAPI PET-CT in patients with rising CA-125 (particularly 35-70 U/mL) but negative conventional imaging:
- FAPI PET-CT was positive in 82.93% of such cases when CT, MRI, and FDG PET-CT were negative 7
- Detection rates were 88.24% in high CA-125 group vs. 79.17% in low CA-125 group 7
- FAPI-positive patients had significantly different progression-free survival compared to FAPI-negative patients (p=0.016) 7
Important Limitations and Caveats
FDG PET-CT Limitations
- Poor detection of subcentimeter metastases due to spatial resolution 1
- Bladder activity obscures pelvic lesions 1
- Difficulty distinguishing post-surgical inflammation from tumor 1
FAPI PET-CT Limitations
- Not FDA-approved or guideline-endorsed for clinical use in ovarian cancer
- Limited availability (investigational tracer)
- May show uptake in inflammatory conditions (e.g., bloody ascites) 8
- Smaller evidence base compared to FDG PET-CT
- No established protocols for interpretation or management decisions
Practical Clinical Algorithm
In current clinical practice, follow this approach:
Initial staging: CT chest/abdomen/pelvis with IV contrast 9, 1
Suspected recurrence with positive CT: Use FDG PET-CT for extent of disease and treatment planning 1
Suspected recurrence with negative/indeterminate CT:
Treatment response assessment: CT with contrast + FDG PET-CT 1
Preoperative peritoneal mapping: CT remains standard; FAPI PET-CT may provide complementary information in research protocols 8, 5
Critical point: FAPI PET-CT should currently be considered only within clinical trials or specialized centers with research protocols, not as standard-of-care imaging. The superior detection rates for peritoneal disease are promising but require validation in prospective trials before guideline incorporation.